

References

I-239

1. Weiss JM, Csozsi T, Maglakelidze M, et al: Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol.* 2019; 30(10):1613-1621.
2. Daniel D, Kuchava V, Bondarenko I, et al: Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. *Int J Cancer.* 2021;148(10): 2557-2570.
3. National Comprehensive Cancer Network (NCCN). Trilaciclib. NCCN Drugs and Biologics Compendium®. 2021.
4. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Trilaciclib.
5. Micromedex DrugDex Compendium®. 2021. Trilaciclib.
6. [Trilaciclib] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated [2021].
7. Trilaciclib. Lexi-Drugs. Hudson, OH: Lexicomp, 2021.
8. Cosela (trilaciclib) for injection, for intravenous use [package insert]. G1 Therapeutics, Inc. Durham, NC. Revised 2/2021.
9. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.